Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26068421 | 0.88 | — | — | |
| SCHEMBL22598549 | 0.86 | METTL3 (0.39) | METTL3 | |
| SCHEMBL26068422 | 0.86 | METTL3 (0.39) | METTL3 | |
| SCHEMBL22815042 | 0.82 | ADK (0.30) | — | |
| SCHEMBL24971053 | 0.80 | CA2 (0.32) | — | |
| SCHEMBL2611649 | 0.77 | — | — | |
| SCHEMBL20810881 | 0.77 | ADK (0.30) | — | |
| SCHEMBL22327400 | 0.77 | TYMP (0.30) | — | |
| SCHEMBL22327402 | 0.77 | TYMP (0.30) | — | |
| SCHEMBL25754037 | 0.77 | TYMP (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127299-A1 | NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF | LG ELECTRONICS INC. (KR) | 2022-04-28 | — | — | US | disclosed |
| US-10822653-B1 | Nucleotide cleavable linkers and uses thereof | Singular Genomics Systems, Inc. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200340051-A1 | NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2020-10-29 | — | — | US | disclosed |
| US-10738072-B1 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2020-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200340051-A1 | NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF | NUDT21, CPSF7, DCLRE1A | METTL3 920/4885 |
| US-20220127299-A1 | NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF | NUDT21, CPSF7, DCLRE1A | METTL3 920/4885 |
| US-10822653-B1 | Nucleotide cleavable linkers and uses thereof | NUDT21, CPSF7, DCLRE1A | METTL3 920/4885 |
| US-10738072-B1 | Nucleotide analogues | NUDT1, POLN, TYMP | METTL3 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.